CORRECTED **VERSION***

(30) Priority Data:

98402540.3

13 October 1998 (13.10.98)

136. Ser. No. 10,516,

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: WO 00/22001 (11) International Publication Number: A2 C07K 147/05 (43) International Publication Date: 20 April 2000 (20.04.00) PCT/EP99/07671 (21) International Application Number:

PP

(22) International Filing Date: 13 October 1999 (13.10.99)

(71) Applicant (for all designated States except SANOFI-SYNTHELABO [FR/FR]; 174, avenue de

France, F-75013 Paris (FR), (72) Inventors; and

(75) Inventors/Applicants (for US only): RENARD, Stephane [FR/FR]; 290, avenue Napoléon Bonaparte, F-92500 Rueil Malmaison (FR). AVENET, Patrick [FR/FR]; 50, rue de Vauhallan, F-91120 Palaiseau (FR).

(74) Agents: ERNEST GUTMANN-YVES PLASSERAUD S.A. et al.; 3, rue Chauveau-Lagarde, F-75008 Paris (FR).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: A NEW POTASSIUM CHANNEL OF THE ERG FAMILY

(57) Abstract

Herg4 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing herg4 polypeptides and polynucleotides in the design of protocols for the treatment of (i) dysfunctions or diseases, including, but not limited to, epilepsy, migraine, cell proliferation, comportmental troubles, among others and diagnostic assays for such conditions.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	នេ	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvis	\$Z	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TC	Торо
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Talikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Paso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia ·	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malewi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ.	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	ΥU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KР	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD.	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EB	Estonia	LR	Liberia	SG	Singapore		



WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. (88) Date of publication of the international search report: 21 September 2000 (21.09.00)

(57) Abstract ·

Herg4 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing herg4 polypeptides and polynucleotides in the design of protocols for the treatment of (i) dysfunctions or diseases, including, but not limited to, epilepsy, migraine, cell proliferation, comportmental troubles, among others and diagnostic assays for such conditions.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM AT A AU A AZ AZ BA B	Albania Armenia Austria Australia Azerbaijan	es Fi Fr Ga	Spain Finland France	LS LT LU	Lesotho Lithuania Luxembourg	SI SK	Slovenia Slovakia	
AT A AU A AZ A BA	Austria Australia	FR	Prance				Slovakia	
AU AZ A	Australia			LU	Invambance	(3)		
AZ A		GA			CERCITOOUS	SN	Senegal	
BA E	Azerbaijan		Gabon	LV	Latvia	SZ	Swaziland	
		GB	United Kingdom	MC	Мопасо	TD	Chad	
DD 1	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo	
DD 1	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan	
BE I	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan	
	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey	
	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago	
BJ I	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine	
BR 1	Brazil	IL	Israel	MR	Mauritania	UC	Uganda	
BY I	Belarus	18	Iceland	MW	Malawi	US	United States of America	
CA (Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan	
CF (Central African Republic	1b	Japan	NE	Niger	VN	Viet Nam	
CG (Congo	KB	Kenya	NL	Netherlands	YU	Yngoslavia	
CH S	Switzerland	KĢ	Kyrgyzstan	NO	Norway	zw	Zimbabwe	
CI (Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		2	
CM (Cameroon		Republic of Korea	PL	Poland			
CN (China	KR	Republic of Korea	PT	Portugal			
CU (Cuba	КZ	Kazakatan	RO	Romania			
CZ (Czech Republic	LC	Saint Lucia	RU	Russian Pederation			
DE (Germany	LI	Liechtenstein	SD	Sudan			
DK 1	Denmark	LK	Sri Lanka	SE	Sweden			
ee i	Estonia	LR	Liberia	SG	Singapore			

Inte onal Application No PCT/EP 99/07671

A. CLASSFICATION OF SUBJECT MATTER
IPC 7 C12N15/12 C07K14/705 C07K16/28 G01N33/566 According to International Patent Classification (IPC) or to both national classification and IPC B. FELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K C12N Documentation exerched other than minimum documentation to the extent that such documents are included in the fields exerched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Chation of document, with indication, where appropriate, of the relevant passages Relevant to daim No. WARMKE JW ET AL: "A family of potassium 1-3, 6-17.19 channel genes related to eag in Drosophila and mammals" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 91, no. 8, 12 April 1994 (1994-04-12), pages 3438-3442, XP002092026 abstract; figure 1 Y EMEST20 DATABASE 1-3, Accession number U69184 6 - 17, 1908-JAN-1998 (Rel. 54, Created) Zollo M., et al. Human DRES 61 mRNA sequence. XP002095400 the whole document Further documents are listed in the continuation of box C. Patent family members are fisted in annex. Special estagortes of cited documents: "I" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance Invention earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubte on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person eldled in the art. "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of making of the international search report Date of the actual completion of the international search 18 May 2000 31/05/2000 Name and mailing address of the ISA Authorized afficer European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijawijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3018 Gurdjian, D

3

Inte. .onal Application No PCT/EP 99/07671

PCT/EP 99/07			
Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.		
TORAL J ET AL: "Use of cultured human neuroblastoma cells in rapid discovery of the voltage-gated potassium-channel blockers." J PHARM PHARMACOL, SEP 1994, 46 (9) P731-4, XP002095398 ENGLAND the whole document	17,19		
SHI W ET AL: "Cloning of a mammalian elk potassium channel gene and EAG mRNA distribution in rat sympathetic ganglia." J PHYSIOL (LOND), SEP 15 1998, 511 (PT 3) P675-82, XP002095399 ENGLAND abstract; figure 1	1-3, 6-13,16, 17,19		
SHI W ET AL: "Identification of two nervous system-specific members of the erg potassium channel gene family." J NEUROSCI, DEC 15 1997, 17 (24) P9423-32, XP002095412 UNITED STATES the whole document	1-3, 6-13,16, 17,19		
TITUS SA ET AL: "The Drosophila erg K+ channel polypeptide is encoded by the seizure locus" JOURNAL OF NEUROSCIENCE, vol. 17, no. 3, 1 February 1997 (1997-02-01), pages 875-881, XP002092027 abstract; figure 1	1-3, 6-13,16, 17,19		
WO 99 37677 A (MOCHIZUKI SHINOBU ;MIYAKE AKIRA (JP); YOKOI HIROMICHI (JP); YAMANO) 29 July 1999 (1999-07-29) abstract; figures SEQ.ID.1,2	1-11		
WO 99 43696 A (AXYS PHARM INC) 2 September 1999 (1999-09-02) abstract; figure SEQ.ID.20	1-3,6-16		
MIYAKE AKIRA ET AL: "New ether-a-go-go K+channel family members localized in human telencephalon." JOURNAL OF BIOLOGICAL CHEMISTRY AUG. 27, 1999, vol. 274, no. 35, 27 August 1999 (1999-08-27), pages 25018-25025, XP000907262 ISSN: 0021-9258 the whole document	1-11		
	neuroblastoma cells in rapid discovery of the voltage-gated potassium-channel blockers." J PHARM PHARMACOL, SEP 1994, 46 (9) P731-4, XP002095398 ENGLAND the whole document SHI W ET AL: "Cloning of a mammalian elk potassium channel gene and EAG mRNA distribution in rat sympathetic ganglia." J PHYSIOL (LOND), SEP 15 1998, 511 (PT 3) P675-82, XP002095399 ENGLAND abstract; figure 1 SHI W ET AL: "Identification of two nervous system-specific members of the erg potassium channel gene family." J NEUROSCI, DEC 15 1997, 17 (24) P9423-32, XP002095412 UNITED STATES the whole document TITUS SA ET AL: "The Drosophila erg K+ channel polypeptide is encoded by the seizure locus" JOURNAL OF NEUROSCIENCE, vol. 17, no. 3, 1 February 1997 (1997-02-01), pages 875-881, XP002092027 abstract; figure 1 WO 99 37677 A (MOCHIZUKI SHINOBU ;MIYAKE AKIRA (JP); YOKOI HIROMICHI (JP); YAMANO) 29 July 1999 (1999-07-29) abstract; figures SEQ.ID.1,2 WO 99 43696 A (AXYS PHARM INC) 2 September 1999 (1999-09-02) abstract; figure SEQ.ID.20 MIYAKE AKIRA ET AL: "New ether-a-go-go K+ channel family members localized in human telencephalon." JOURNAL OF BIOLOGICAL CHEMISTRY AUG. 27, 1999, vol. 274, no. 35, 27 August 1999 (1999-08-27), pages 25018-25025, XP000907262 ISSN: 0021-9258		

unernational application No.

PCT/EP 99/07671

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This inten	national Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. 🔲 🖁	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
-	
	Claims Nos.: 18 20 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
· (Claim 18 relating to agonists and claim 20 relating to antagonists to the polypeptide of
	Claim 10 could not be searched as its subject-matter was insufficiently disclosed.
3 🗀 🖁	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This Inter	mational Searching Authority found multiple inventions in this international application, as follows:
1. 🔲	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2 🗌 🤅	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. []	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
	The state of the state of the country, it is covered by Genire 1004.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

International Application No. PCT/EP 99 07671

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 18 20

Claim 18 relating to agonists and claim 20 relating to antagonists to the polypeptide of claim 10 could not be searched as its subject-matter was insufficiently disclosed.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

information on patent family members

Inte. onal Application No PCT/EP 99/07671

Patent document cited in search report	t	Publication date		atent family nember(s)	Publication date
WO 9937677	A	29-07-1999	AU	1982799 A	09-08-1999
WO 9943696	Α	02-09-1999	AU	2780999 A	15-09-1999

Form PCT/ISA/210 (petent family annex) (July 1992)